Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 18.71M 16.4M 15.12M 14.16M 26.55M 1.76B 27.1M 70.33M 872M 70.25M 68.72M 3.02B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 40.72M 35.7M 32.91M 30.81M 57.77M 3.84B 58.97M 153M 1.9B 153M 150M 6.58B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23-10-23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
23-10-20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
23-10-20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
23-10-19	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
23-10-16	Irras Obtains Extension for SEK20 Million Loan	MT
23-10-15	Irras extends SEK 20 million short-term loan	FW
23-10-02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
23-09-18	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
23-05-22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
23-05-21	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
23-02-20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

23-10-20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
23-10-19	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
23-10-19	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
23-10-16	IRRAS publishes prospectus	AQ
23-10-15	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	2021-06-30
Griffen Stapp DFI	Director of Finance/CFO	40	2021-06-16
Sten Gustafsson IRC	Investor Relations Contact	-	2021-03-08

IRRAS AB (publ) Stock London S.E.

Stocks

0GDW

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB (publ)

Latest news : IRRAS AB (publ)

Analysts' recommendations: IRRAS AB (publ)

Press Releases: IRRAS AB (publ)

Quotes and Performance

Managers and Directors: IRRAS AB (publ)

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	2015-05-31
Marios Fotiadis CHM	Chairman	53	2020-08-17
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	2017-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB (PUBL)	-3.63%	-70.75%	-	-	16.9M
STRYKER CORPORATION	+5.25%	+8.09%	-14.78%	+12.08%	128B
SMITH & NEPHEW PLC	-0.65%	+1.20%	+3.41%	-8.11%	12.77B
GLAUKOS CORPORATION	+1.30%	+10.51%	+42.91%	+109.94%	8.48B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-3.88%	-6.41%	-50.34%	-72.89%	3.79B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.38%	-0.97%	+17.98%	+37.20%	2.52B
L&C BIO CO.,LTD	-9.06%	+4.50%	+229.48%	+156.69%	1.55B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-8.75%	-13.25%	-26.46%	-23.39%	1.53B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-2.80%	-3.48%	-1.78%	-22.72%	1.53B
Average	-2.51%	-0.05%	+25.05%	+23.60%	19.96B
Weighted average by Cap.	+3.91%	+6.82%	-8.20%	+14.78%

	2023	2024
Net sales	42.88M 4.41M 3.87M 3.57M 3.34M 6.26M 416M 6.39M 16.59M 206M 16.58M 16.21M 714M	57.98M 5.97M 5.23M 4.82M 4.52M 8.47M 563M 8.65M 22.44M 278M 22.41M 21.92M 965M
Net income	-209M -21.5M -18.85M -17.38M -16.27M -30.51M -2.03B -31.14M -80.82M -1B -80.74M -78.98M -3.48B	-95.98M -9.88M -8.66M -7.99M -7.48M -14.02M -932M -14.31M -37.14M -461M -37.1M -36.29M -1.6B
Net Debt	43.85M 4.51M 3.96M 3.65M 3.42M 6.4M 426M 6.54M 16.97M 210M 16.95M 16.58M 730M	214M 22.01M 19.3M 17.79M 16.65M 31.23M 2.08B 31.87M 82.72M 1.03B 82.64M 80.84M 3.56B